We strive to help healthcare professionals in the UK and Ireland deliver the best possible care for people living with skin conditions
At LEO Pharma, we interact with healthcare professionals (HCPs) and healthcare organisations (HCOs) to provide scientific or educational knowledge, or to support our medical research.
We are committed to upholding high ethical standards and to ensuring compliance when interacting with HCPs and HCOs, and we are mindful that all interactions should be conducted in line with the LEO Pharma value of integrity.
Transparency in our interactions with HCPs and HCOs
At LEO Pharma, we report and disclose any engagements and/or payments and expenses (transfers of value) made on behalf of LEO Pharma to HCPs and HCOs in accordance with applicable laws, ethical codes and regulations.
Reflecting our desire to be transparent, ethical and respectful to our partners, our work with patient organisations is governed by the framework provided by our values, the LEO Code of Conduct together with the ABPI and IPHA Codes of Practice in the UK and Ireland respectively.
Due to the COVID-19 outbreak, the ABPI agreed that the 2019 data on disclosures would initially be published in aggregate format on their website and named individual level HCP/HCO payments would be published at a later date. The 2019 disclosure data was subsequently re-published on 27th November 2020, disaggregated as normal on the ABPI website.
Visit the ABPI or IPHA disclosure pages to find out more.
Transparency in our collaborative working with the NHS
LEO Pharma is committed to advancing the standard of care in dermatology. One way in which we can do this is to partner with others, including with the NHS.
Below you can find an executive summary of our current on-going Collaborative Working Projects, including Joint Working Projects in the the UK. Click on the link(s) to find out more:
MAT-69502 November 2023